Glycaemic control and cost analysis when changing from gliclazide co-administered with metformin to pre- combined glibenclamide-metformin tablets in type 2 diabetes mellitus

Medical Journal of Malaysia

Volumn 67, Issue 1, 2012, Pages 21-24

  Lim, P C ^a   Lim, Shueh Lin ^a   Oiyammaal, C ^a  

^a Pantai Medical Centre   (Malaysia)

Author keywords

Cost effective; Glibenclamide metformin; Gliclazide co administered with metformin; Glycosylated haemoglobin

Indexed keywords

GLIBENCLAMIDE PLUS METFORMIN; GLICLAZIDE; HEMOGLOBIN A1C; METFORMIN; PHARMANIAGA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; FEMALE; GLYCEMIC CONTROL; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS;

BLOOD GLUCOSE; COSTS AND COST ANALYSIS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; GLICLAZIDE; GLYBURIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; RETROSPECTIVE STUDIES; TABLETS;

EID: 84859478533     PISSN: 03005283     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999;131: 281-303.
2. Kahn S. The importance of the ß-cell in the pathogenesis of type 2 diabetes mellitus. Am J med. 2000; 108(suppl 6a): 9S-14S.
3. U.K. Prospective Diabetes Study Group. Overview of 6 years' therapy of type II diabetes: a progressive disease (UKPDS 16). Diabetes 1995; 44(11): 1249-58.
4. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008 Oct 9; 359(15): 1577-89.
5. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999 Jun 2; 281(21): 2005-12.
6. Hermann LS, Scherstén B, Bitzén PO, Kjellström T, Lindgärde F, Melander A. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care 1994 Oct; 17(10): 1100-9
7. Blonde L, Wogen J, Kreilick C, Seymour AA. Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co-administered with metformin. Diabetes Obes Metab. 2003 Nov; 5(6): 424-31.
8. A report of Pharmaceutical Services Division, Ministry of Health Malaysia. Private sector medicines retail price list 2011 (2nd Ed). 2010 Oct.: 210-4.
9. Duckworth W, Marcelli M, Padden M, et al. Improvements in glycemic control in type 2 diabetes patients switched from sulfonylurea coadministered with metformin to glyburide-metformin tablets. J Manag Care Pharm. 2003 May-Jun;9(3): 256-62.
10. U.K. Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000 Aug 12; 321(7258): 405-12
11. Baba S, Nakagawa S, Takebe K, et al. Comparison of gliclazide and glibenclamide treatment in non-insulindependent diabetes. Tohoku J Exp Med 1983; 141 (Suppl.): 693-706.
12. Garber AJ, Donovan DS Jr, Dandona P, Bruce S, Park JS. Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. J Clin Endocrinol Metab. 2003 Aug; 88(8): 3598-604.
13. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009 Jan; 32(1): 193-203.
14. Ministry of Health Malaysia. Clinical Practice Guidelines: Management of Type 2 Diabetes Mellitus (4th Ed). 2009 May.
15. Howlett H, Porte F, Allavoine T, Kuhn T, Nicholson G. The development of an oral antidiabetic combination tablet: design, evaluation and clinical benefits for patients with type 2 diabetes. Curr Med Res Opin. 2003; 19(3): 218-25.
16. Donahue SR, Turner KC, Patel S. Pharmacokinetics and pharmacodynamics of glyburide/metformin tablets (Glucovance) versus equivalent doses of glyburide and metformin in patients with type 2 diabetes. Clin Pharmacokinet. 2002; 41(15): 1301-9.
17. Melikian C, White TJ, Vanderplas A, Dezii CM, Chang E. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther. 2002 Mar; 24(3): 460-7.
18. A publication of Pharmaceutical Services Division and Clinical Research Centre, Ministry of Health Malaysia. Malaysian statistics on medicine 2007. 2010 Oct: 21-4.